AstraZeneca wants into the obesity-drug business. The British drugmaker made a roughly $10 billion offer for Rhythm Pharmaceuticals, which makes treatments for rare forms of obesity, at $124 a share. Rhythm's stock had been trading around $95. On the report it closed up 28%, at about $111, valuing the company near $7.6 billion. AstraZeneca, worth close to $300 billion, barely moved.
That split is the whole shape of a takeover. The company being bought jumps toward the offer price. The buyer, many times larger, shrugs, because one deal is a small part of its value and investors debate whether it overpaid. If you didn't already own Rhythm before the news, you couldn't catch the 28% pop. By the time you read about it, the jump already happened.
Why AstraZeneca is shopping
AstraZeneca has become a cancer-drug powerhouse and is now chasing one of the fastest-growing markets in medicine, obesity treatments. It has targeted $80 billion in sales by 2030, up from $58.7 billion last year, and analysts say it will have to keep buying to get there. It has been doing exactly that, with a $1.2 billion licensing deal in January and a $39 billion purchase of a rare-disease firm back in 2021. Rhythm's treatments for rare obesity would add to that pipeline. We hold AstraZeneca in 20 of our model books. We don't hold Rhythm. Our model books changed little this week: a CoreWeave trim and two small swaps, nothing in the North Star.
This is one deal in a busy season for health-care mergers. It's a good moment to understand how they actually pay out for ordinary investors, which is rarely the way the headline suggests.
Our read
This is an Investments and Risk story, module IN04, about chasing takeovers. Every so often a stock you own, or wish you owned, gets a buyout offer and jumps 28% in a day. It's tempting to go hunting for the next one. Resist it. By the time a deal is public, the pop is gone. And guessing which small company gets bought next is a coin flip with real costs. For every rumor that comes true, several don't, and the stock gives back the hope it ran up on.
The better way to benefit from mergers is boring: own the whole field through a fund, so you hold the targets before anyone knows they're targets. If you own a broad health-care or total-market fund, you already owned a sliver of Rhythm this morning and you got the pop automatically, with no guessing. Here's the check this week. If you catch yourself eyeing a single stock because someone says it might get bought, stop and ask whether you'd want to own it if the deal never happens. If the answer is no, you're gambling on the rumor, not investing in the company. We hold AstraZeneca because we like the business, not because we predicted a deal. If you want to talk through how mergers flow into a diversified portfolio, that's fifteen minutes.